Dermatology News and Research RSS Feed - Dermatology News and Research

Dermatology is the branch of medicine dealing with the skin and its diseases. Dermatologists take care of diseases and cancers of the skin, scalp, hair, and nails.
Vascular receptor autoantibodies implicated in SSc-PAH

Vascular receptor autoantibodies implicated in SSc-PAH

medwireNews: Autoantibodies to endothelin receptor type A and angiotensin receptor type-1 predict the development of, and mortality from, systemic sclerosis-associated pulmonary arterial hypertension, research suggests. [More]
HRQoL goals may improve outcome in PAH

HRQoL goals may improve outcome in PAH

Health-related quality of life before and during treatment for pulmonary arterial hypertension is significantly associated with survival, Brazilian researchers report. [More]
Regeneron, Sanofi announce initiation of dupilumab Phase 3 study in adults with atopic dermatitis

Regeneron, Sanofi announce initiation of dupilumab Phase 3 study in adults with atopic dermatitis

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the first patients have been dosed in a Phase 3 clinical study of dupilumab, an investigational therapy that blocks IL-4 and IL-13 signaling, in adults with moderate-to-severe atopic dermatitis (AD) that is not adequately controlled with topical AD medications. [More]
Patients with severe psoriasis more likely to have uncontrolled hypertension, shows research

Patients with severe psoriasis more likely to have uncontrolled hypertension, shows research

Patients with more severe psoriasis are also more likely to have uncontrolled hypertension, according to new research by a team at the Perelman School of Medicine at the University of Pennsylvania. [More]

Hypertensive patients who have psoriasis may need stricter blood pressure control

People with hypertension who also have psoriasis may benefit from tighter blood pressure control, say researchers, particularly if their psoriasis is moderate or severe. [More]
Ebola outbreak emphasizes the importance of monitoring disease burden in developing countries

Ebola outbreak emphasizes the importance of monitoring disease burden in developing countries

A study recently published in the Journal of the American Academy of Dermatology shows that for Ebola, measles, syphilis and many other conditions with skin manifestations the mortality rates are hundreds of times higher in developing countries than they are in developed countries. [More]

Noninvasive measure has prognostic value in PAH

Estimated right atrial pressure, measured using echocardiography, may be a useful prognostic indicator in patients with pulmonary arterial hypertension, a study suggests. [More]

Galderma announces launch of new global initiative to support dermatology community

Galderma is proud to announce the launch of a new global initiative under the SKINPACT Programme that will provide support for two new projects in the field of community dermatology. The winning entries will be awarded funding to implement future projects to help shape advances in Community Leadership and Excellence in Education to improve communities and patient quality of life. [More]
Chronic contact allergy from metal orthopedic implant linked to aggressive form of skin cancer

Chronic contact allergy from metal orthopedic implant linked to aggressive form of skin cancer

In rare cases, patients with allergies to metals develop persistent skin rashes after metal devices are implanted near the skin. New research suggests these patients may be at increased risk of an unusual and aggressive form of skin cancer. [More]
Endo International enters into definitive agreement to acquire Auxilium Pharmaceuticals

Endo International enters into definitive agreement to acquire Auxilium Pharmaceuticals

Endo International plc and Auxilium Pharmaceuticals, Inc. today announced that they have entered into a definitive agreement under which Endo will acquire all of the outstanding shares of common stock of Auxilium for a per share consideration of $33.25 in a cash and stock transaction. [More]
NIH announces high-risk, high-reward grants for UCSF researchers

NIH announces high-risk, high-reward grants for UCSF researchers

UC San Francisco researchers received five awards announced this week by the National Institutes of Health (NIH) for high-risk, high-reward scientific research projects. Their work will focus on novel approaches for diagnosing and treating diseases ranging from autoimmune and chronic inflammatory diseases, to cancer, diabetes and neurological disorders. [More]
UCSF researchers receive five NIH awards for high-risk scientific research projects

UCSF researchers receive five NIH awards for high-risk scientific research projects

UC San Francisco researchers received five awards announced this week by the National Institutes of Health for high-risk, high-reward scientific research projects. Their work will focus on novel approaches for diagnosing and treating diseases ranging from autoimmune and chronic inflammatory diseases, to cancer, diabetes and neurological disorders. [More]
Elite dermatologic surgeon to deliver presentation at Syneron Investor Conference

Elite dermatologic surgeon to deliver presentation at Syneron Investor Conference

Elite dermatologic surgeon Dr. David Amron was among few physicians asked to speak at the Syneron Investor Conference Sept. 17 in New York. [More]
Vitamin D supplement significantly reduces symptoms of winter-related atopic dermatitis

Vitamin D supplement significantly reduces symptoms of winter-related atopic dermatitis

A study conducted in more than 100 Mongolian schoolchildren found that daily treatment with a vitamin D supplement significantly reduced the symptoms of winter-related atopic dermatitis, a type of eczema. [More]
Halozyme's PEGPH20 receives FDA Orphan Drug designation for treatment of pancreatic cancer

Halozyme's PEGPH20 receives FDA Orphan Drug designation for treatment of pancreatic cancer

Halozyme Therapeutics, Inc. today announced that the U.S. Food and Drug Administration has granted Orphan Drug designation for PEGylated recombinant human hyaluronidase (PEGPH20) for the treatment of pancreatic cancer. [More]
Cultural, historical forces contribute to rise in cases of melanoma

Cultural, historical forces contribute to rise in cases of melanoma

A century's worth of cultural and historical forces have contributed to the rise in the incidence of melanoma, including changes in fashion and clothing design, according to an intriguing, retrospective research study conducted by investigators in the Ronald O. Perelman Department of Dermatology at NYU Langone Medical Center. [More]
Mission Pharmacal adds Ovace Plus Lotion to its range of product offerings

Mission Pharmacal adds Ovace Plus Lotion to its range of product offerings

Itch. Scratch. Repeat. Irritating skin conditions, such as seborrheic dermatitis (SD), can create a distracting, uncomfortable vicious circle for those affected. [More]
Research shows resveratrol in grapes inhibits bacteria that cause acne

Research shows resveratrol in grapes inhibits bacteria that cause acne

Got grapes? UCLA researchers have demonstrated how resveratrol, an antioxidant derived from grapes and found in wine, works to inhibit growth of the bacteria that causes acne. [More]
Bausch + Lomb’s sub-micron loteprednol etabonate ophthalmic gel meets primary endpoint

Bausch + Lomb’s sub-micron loteprednol etabonate ophthalmic gel meets primary endpoint

Bausch + Lomb, a wholly owned subsidiary of Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX), today announced that its next generation sub-micron gel formulation of loteprednol etabonate was statistically superior to placebo (vehicle gel) in eliminating inflammation and pain following cataract surgery by study day eight, the primary endpoints in the first Phase 3, multi-center, double-masked, vehicle-controlled, parallel-group study. [More]
Combination therapy achieves greater progression-free survival, response rates in melanoma

Combination therapy achieves greater progression-free survival, response rates in melanoma

Combination therapy with both BRAF inhibitor vemurafenib and MEK inhibitor cobimetinib achieves greater progression-free survival and response rates than vemurafenib plus placebo in BRAF-mutation positive melanoma, according to phase III data presented at the ESMO 2014 Congress in Madrid, Spain. [More]